A federal jury in Marshall, Texas, found that a Japanese pharmaceutical company infringed on a cancer treatment patent that a U.S. global biotech company developed.

The four-day trial concluded, and jurors awarded Seagen, a Bothell, Washington-based company, $41.8 million. U.S. Chief Judge Rodney Gilstrap presided over the case in the U.S. District Court of the Eastern District of Texas.